EFG International AG Invests $2.93 Million in Tarsus Pharmaceuticals, Inc. $TARS

EFG International AG purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 46,552 shares of the company’s stock, valued at approximately $2,932,000.

A number of other hedge funds have also recently added to or reduced their stakes in TARS. BlackRock Inc. purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $242,705,000. RTW Investments LP raised its stake in shares of Tarsus Pharmaceuticals by 5.0% during the 4th quarter. RTW Investments LP now owns 3,335,320 shares of the company’s stock worth $273,096,000 after buying an additional 157,884 shares in the last quarter. Deep Track Capital LP raised its stake in shares of Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after buying an additional 127,470 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in shares of Tarsus Pharmaceuticals by 16.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock valued at $157,223,000 after buying an additional 310,638 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 1.1%

TARS opened at $70.65 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. The company has a market cap of $3.10 billion, a price-to-earnings ratio of -64.82 and a beta of 0.53. Tarsus Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $85.25. The business’s fifty day moving average is $64.05 and its two-hundred day moving average is $65.24.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. Analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TARS. Guggenheim dropped their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Tuesday, July 21st. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Mizuho decreased their target price on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $90.50.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, Director William J. Phd Link sold 12,500 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.12, for a total value of $776,500.00. Following the sale, the director directly owned 106,786 shares in the company, valued at $6,633,546.32. This represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.08, for a total transaction of $183,384.32. Following the transaction, the director directly owned 2,233 shares of the company’s stock, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 39,850 shares of company stock valued at $2,452,821. Insiders own 9.64% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.